Mattila Juho, Kallio Johanna, Löyttyniemi Eliisa, Nuutila Pirjo, Koffert Jukka
Department of Gastroenterology, Turku University Hospital, Turku, Finland.
InFlames Flagship Programme, Turku, Finland.
Dig Dis. 2025;43(1):104-114. doi: 10.1159/000542379. Epub 2024 Nov 13.
Diagnostics of small bowel Crohn's disease (CD) can be difficult. Combined positron emission tomography-magnetic resonance enterography (PET-MRE) can be used to evaluate intestinal metabolism, but clinical use has been limited due to accessibility, costs, absence of standardized methods, and diagnostic thresholds. Our aim was to show that combined PET-MRE can be used to diagnose active small bowel CD.
We performed a fusion PET-MRE scan with [18F]-FDG tracer to 30 patients with suspected small bowel CD in colonoscopy. Standardized uptake values (SUVs) were measured from small bowel. The diagnosis was confirmed with small bowel capsule endoscopy. Clinicians chose appropriate medication to each patient blinded from SUV results. Endoscopic, laboratory, and MRE findings were investigated in relation to SUV.
Fusion PET-MRE outperformed MRE in diagnostic accuracy. Patients diagnosed with CD (N = 24) had higher SUV than patients not diagnosed with CD (N = 6) (3.34 vs. 1.84, p = 0.022). A diagnostic cut-off at SUV at 2.5 could be used (AUROC = 0.81). A higher SUV predicts need for immunosuppressive medication (p = 0.0026) and biologics (p = 0.0005). SUV correlates positively with Simple Endoscopic Score for Crohn's Disease (SES-CD), fecal calprotectin, and CRP and negatively with Hb and serum albumin.
In future, [18F]-FDG PET-MRE can be used in diagnostics of small bowel CD as a safe alternative for capsule endoscopy. High SUV can predict a more progressive disease course and need for more advanced therapies.
Diagnostics of small bowel Crohn's disease (CD) can be difficult. Combined positron emission tomography-magnetic resonance enterography (PET-MRE) can be used to evaluate intestinal metabolism, but clinical use has been limited due to accessibility, costs, absence of standardized methods, and diagnostic thresholds. Our aim was to show that combined PET-MRE can be used to diagnose active small bowel CD.
We performed a fusion PET-MRE scan with [18F]-FDG tracer to 30 patients with suspected small bowel CD in colonoscopy. Standardized uptake values (SUVs) were measured from small bowel. The diagnosis was confirmed with small bowel capsule endoscopy. Clinicians chose appropriate medication to each patient blinded from SUV results. Endoscopic, laboratory, and MRE findings were investigated in relation to SUV.
Fusion PET-MRE outperformed MRE in diagnostic accuracy. Patients diagnosed with CD (N = 24) had higher SUV than patients not diagnosed with CD (N = 6) (3.34 vs. 1.84, p = 0.022). A diagnostic cut-off at SUV at 2.5 could be used (AUROC = 0.81). A higher SUV predicts need for immunosuppressive medication (p = 0.0026) and biologics (p = 0.0005). SUV correlates positively with Simple Endoscopic Score for Crohn's Disease (SES-CD), fecal calprotectin, and CRP and negatively with Hb and serum albumin.
In future, [18F]-FDG PET-MRE can be used in diagnostics of small bowel CD as a safe alternative for capsule endoscopy. High SUV can predict a more progressive disease course and need for more advanced therapies.
小肠克罗恩病(CD)的诊断可能具有挑战性。正电子发射断层扫描-磁共振小肠造影(PET-MRE)联合检查可用于评估肠道代谢,但由于可及性、成本、缺乏标准化方法和诊断阈值等因素,其临床应用受到限制。我们的目的是证明PET-MRE联合检查可用于诊断活动期小肠CD。
我们对30例结肠镜检查怀疑患有小肠CD的患者进行了[18F]-FDG示踪剂的融合PET-MRE扫描。从小肠测量标准化摄取值(SUV)。通过小肠胶囊内镜检查确诊。临床医生在不知道SUV结果的情况下为每位患者选择合适的药物。研究了内镜、实验室和MRE检查结果与SUV的关系。
融合PET-MRE在诊断准确性方面优于MRE。诊断为CD的患者(N = 24)的SUV高于未诊断为CD的患者(N = 6)(3.34对1.84,p = 0.022)。SUV为2.5时可作为诊断临界值(曲线下面积 = 0.81)。较高的SUV预示着需要免疫抑制药物治疗(p =
0.0026)和生物制剂治疗(p = 0.0005)。SUV与克罗恩病简易内镜评分(SES-CD)、粪便钙卫蛋白和CRP呈正相关,与血红蛋白和血清白蛋白呈负相关。
未来,[18F]-FDG PET-MRE可用于小肠CD的诊断,作为胶囊内镜检查的安全替代方法。高SUV可预测疾病进展更严重且需要更先进的治疗。
小肠克罗恩病(CD)的诊断可能具有挑战性。正电子发射断层扫描-磁共振小肠造影(PET-MRE)联合检查可用于评估肠道代谢,但由于可及性、成本、缺乏标准化方法和诊断阈值等因素,其临床应用受到限制。我们的目的是证明PET-MRE联合检查可用于诊断活动期小肠CD。
我们对30例结肠镜检查怀疑患有小肠CD的患者进行了[18F]-FDG示踪剂的融合PET-MRE扫描。从小肠测量标准化摄取值(SUV)。通过小肠胶囊内镜检查确诊。临床医生在不知道SUV结果的情况下为每位患者选择合适的药物。研究了内镜、实验室和MRE检查结果与SUV的关系。
融合PET-MRE在诊断准确性方面优于MRE。诊断为CD的患者(N = 24)的SUV高于未诊断为CD的患者(N = 6)(3.34对1.84,p = 0.022)。SUV为2.5时可作为诊断临界值(曲线下面积 = 0.81)。较高的SUV预示着需要免疫抑制药物治疗(p =
0.0026)和生物制剂治疗(p = 0.0005)。SUV与克罗恩病简易内镜评分(SES-CD)、粪便钙卫蛋白和CRP呈正相关,与血红蛋白和血清白蛋白呈负相关。
未来,[18F]-FDG PET-MRE可用于小肠CD的诊断,作为胶囊内镜检查的安全替代方法。高SUV可预测疾病进展更严重且需要更先进的治疗。